RespireRx Pharmaceuticals Inc. (RSPI)

0.0010 +0.0001 (+11.11%) At close: 03:39PM EDT

RespireRx Pharmaceuticals Inc.

126 Valley Road
Suite C
Glen Rock, NJ 07452
United States
201 444 4947
https://www.respirerx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 2

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Arnold S. Lippa Ph.D.	Executive Chairman, Interim President, Interim CEO & Chief Scientific Officer	339.6k	N/A	1947
Dr. Jeff Eliot Margolis	Senior VP, CFO, Treasurer, Secretary & Director	321.6k	N/A	1956
Mr. Richard D. Purcell	Senior Vice President of Research & Development	199.86k	N/A	1961
Mr. David Dickason	Senior Vice President of Pre-Clinical Product Development	N/A	N/A	1964
Mr. Marc M. Radin	Controller	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.

Corporate Governance

RespireRx Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.